Total
0
Shares
Image Sourced Shutterstock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Bod Australia gained 20 per cent today after announcing a new solution to help stop the skin ageing process
  • A three-year company research project has found proteins in human cells which can provide antioxidant protective effects when applied to skin cells
  • Bod and research partner UTS are now exploring ways in which these proteins can be incorporated into topical hemp skin creams for anti-ageing

Bod Australia has gained 20 per cent after announcing a new solution to help stop the skin ageing process.

The company teamed up with University of Technology Sydney (UTS) scientists for the past three years to discover this solution.

It discovered that a novel family of proteins found in the human cells provide antioxidant protective effects when applied to skin cells. These proteins help protect the cells against oxidative damage, and increase their tolerance and recovery to UV light.

Additional experiments with the proteins have shown increased levels of antioxidant activity and cellular growth — which refers to cell development and reproduction — and metabolism.

These findings will allow Bod to create a hemp-based body and face cream that will help with anti-ageing. The company will put a delivery system in place for further development. It will hold all global rights to the delivery methods which will be sold to pharmaceutical companies.

Bod CEO Jo Patterson is pleased with the results of this recent discovery.

“The results of this three year collaboration provide Bod with a fantastic commercial opportunity in both the anti ageing market and cannabis markets which are both rapidly growing and ever changing,” Jo said.

Bod and UTS’ immediate focus will now be on exploring ways in which these proteins can be incorporated into topical skin creams for anti-ageing.

Bod Australia is a developer, distributor, and marketer of health and skincare products.

Bod works with plant based extracts, with specific expertise in leveraging the health benefits associated with hemp.

The company has a large distribution footprint in Australia, selling prescription and over the counter products to over 1000 retail outlets, including pharmacies, retail stores and healthcare chains.

The global anti-aging market was worth US$42.5 billion in 2018 and is estimated to grow to US$55.03 billion by 2023, according to the company.

Bod shares reached a high of 63 cents apiece this morning, but have since settled slightly to trade for 58 cents each inside a $51.92 million market cap.

BDA by the numbers
More From The Market Herald
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp (ASX:RAP) secures new licences in Q3 amid revenue slump

ResApp Health (RAP) has released its quarterly activities report for the three months to the end of September 2021.

" Incannex Healthcare (ASX:IHL) lands ethics approval for psychedelic-based anxiety treatment trial

Incannex Healthcare (IHL) has spiked on the ASX today after landing important regulatory approvals to trial a psychedelic-based treatment for severe anxiety.